Categories: News

1155176 B.C. LTD. Announces Upcoming Name Change and Consolidation Effective March 27, 2019

VANCOUVER, BC / ACCESSWIRE / March 25, 2019 / 1155176 B.C. LTD. (“176” or the “Company”) is pleased to announce that it will be changing its name to Canland Health Corp. and consolidating its issued and outstanding class A common shares on the basis of 50 pre-consolidation shares for each 1 post-consolidation share set to concurrently occur effective March 27, 2019. The Company’s new CUSIP after the name change and consolidation will be “137640108”.

For further information please contact:

Ron Miles, CEO & Director
E-mail: rmiles1@telus.net

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of 176. Forward-looking information is based on certain key expectations and assumptions made by the management of 176, and includes the completion of the contemplated name change and consolidation as described herein. Although 176 believes that the expectations and assumptions on which such forward-looking information is based on are reasonable, undue reliance should not be placed on the forward-looking information because 176 can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. 176 disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE: 1155176 B.C. LTD

View source version on accesswire.com:
https://www.accesswire.com/540103/1155176-BC-LTD-Announces-Upcoming-Name-Change-and-Consolidation-Effective-March-27-2019

user

Recent Posts

BioHarvest Sciences Announces Record $2 Million Monthly Sales

VINIA Subscription Growth Drives 101% Year-over-Year Increase in May Product Sales Orders; Cumulative Customer Reviews…

1 hour ago

DirectTrust(R) and Digital Therapeutics Alliance Announce Partnership to Provide Accreditation for Digital Therapeutics Industry

Collaboration to expand existing DirectTrust programs by establishing a new accreditation program for efficacy and…

1 hour ago

Cloud DX Inc. Announces Restructuring Process and the Resignation of 2 Directors

KITCHENER, ON / ACCESSWIRE / June 6, 2024 / Cloud DX Inc. ("Cloud DX") (TSXV:CDX)(OTCQB:CDXFF)…

1 hour ago

Moderna’s Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines…

1 hour ago

Theralase(R) Successfully Destroys Lung Cancer

TORONTO, ON / ACCESSWIRE / June 6, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…

1 hour ago